Goldman Sachs Maintains Buy on Relay Therapeutics, Raises Price Target to $31
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $22 to $31.
Goldman Sachs analyst Salveen Richter maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $22 to $31.